This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Cancer Drug Keytruda Positive in Clinical Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Incyte Provides Updated Data on Cancer Combination Therapies
by Zacks Equity Research
Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.
Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
Incyte Announces Data on Enzyme Inhibitor with Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
The Zacks Analyst Blog Highlights: General Electric, Walt Disney, Merck, Pfizer and Chevron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Electric, Walt Disney, Merck, Pfizer and Chevron
Merck (MRK) Up 2.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Income Stocks to Buy for June 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 5th:
Aduro's Drug Gets Clearance by the FDA for Solid Tumors
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815).
Gilead Single Tablet Regiment for HIV Good in Phase III
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.
UnitedHealth's (UNH) Business Unit Collaborates with Merck
by Zacks Equity Research
UnitedHealth Group, Inc.???s (UNH) information and technology-enabled health services business "Optum" recently announced its collaboration with Merck & Co. Inc (MRK).
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
by Zacks Equity Research
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
Celldex's Immuno-Oncology Pipeline Continues to Impress
by Zacks Equity Research
On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).
The Zacks Analyst Blog Highlights: Merck, 3M, United Technologies, Ford Motor and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, 3M, United Technologies, Ford Motor and Humana
Radius Health Osteoporosis Drug Positive in Phase III Study
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .
Merck Presents Phase II Data on Chronic Cough Candidate
by Zacks Equity Research
Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.
Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?
by Arpita Dutt
Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?
Amgen Evenity Approval Derailed on Cardiovascular Side Effect
by Zacks Equity Research
A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.
Company News for May 19, 2017
by Zacks Equity Research
Companies in the News are: LB,P,INCY,MRK,SHPG
Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
by Zacks Equity Research
Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.